RaiseTrack

Estuary Biotherapeutics Series A (2026)

Estuary Biotherapeutics raised $93 million in a Series A, announced on 2026-10-16. RA Capital Management led the round.

Company
Estuary Biotherapeutics
Round type
Series A
Date
2026-10-16
Amount
$93M
Industry
genetic medicines, biotechnology

Summary

Estuary Biotherapeutics announced a $93 million Series A on 2026-10-16, led by RA Capital Management, with Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund, 4BIO Capital and GV. The company release and 4BIO Capital say 4BIO Capital and GV co-led a $10 million seed and participated in the Series A. The release says total committed financing is $103 million. The seed is not a separate round page.

The release and the Raise Track Update say Pivotal bioVenture Partners and the National Kidney Foundation Innovation Fund. 4BIO Capital's post says Pivotal bioVentures and the National Kidney Foundation. This page uses the release names. A family office connected to an individual living with ADPKD is named in the release and is not given a name, so it is not listed here.

A Form D filed the same day reports $40,654,685 sold of $103,654,385 offered and does not name a round. Those figures are not stored. This page uses the announced $93 million.

Investors

Lead

Participating

Sources

Last verified:

  1. https://estuarybio.com/news/estuary-series-a
    Type: company announcement. Accessed 2026-10-19.
    Company release labeled 16 October 2026, datelined MENLO PARK, Calif., and NEWTON, Mass. Announces a $93 million Series A led by RA Capital Management, with Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund, and a family office connected to an individual living with ADPKD. 4BIO Capital and GV co-led a $10 million seed and also participated in the Series A. Total committed financing is $103 million.
  2. https://www.4biocapital.com/single-post/estuary-biotherapeutics-launches-with-103-million-to-advance-targeted-gene-therapies-for-kidney-dis
    Type: official investor website. Accessed 2026-10-19.
    4BIO Capital post datelined London, 16 October 2026. Confirms the USD 93 million Series A led by RA Capital Management and the USD 10 million seed co-led with GV. Writes Pivotal bioVentures and the National Kidney Foundation.
  3. https://www.fiercebiotech.com/biotech/estuary-emerges-stealth-103m-its-gene-therapies-kidney-disease
    Type: reputable publication. Accessed 2026-10-19.
    Fierce Biotech, labeled Oct 16, 2026, 6:30am. Reports the $93 million Series A led by RA Capital Management and the earlier $10 million seed. Names Deep Track Capital, Biogen New Ventures, UPMC Enterprises, 4BIO Capital and GV.
  4. https://www.biospace.com/deals/estuary-sails-into-kidney-disease-space-with-103m-for-gene-therapies
    Type: reputable publication. Accessed 2026-10-19.
    BioSpace deals article by Annalee Armstrong, October 16, 2026. Reports the $93 million Series A led by RA Capital Management and an earlier $10 million seed. Names Deep Track Capital, Biogen New Ventures and others, plus 4BIO Capital and GV.
  5. https://www.sec.gov/Archives/edgar/data/2138862/000213886226000003/0002138862-26-000003-index.htm
    Type: sec filing. Accessed 2026-10-19.
    SEC Form D filed 2026-10-16. Total amount sold $40,654,685 of an offering amount of $103,654,385. Issuer city Menlo Park, California. The form does not name a round type or the purchasers. Those amounts are not stored on this round. The filing is not a separate page because it is not in Section 3 of the issue.
  6. https://buttondown.com/raisetrack/archive/raise-track-update-2026-10-19/
    Type: other verified public source. Accessed 2026-10-19.
    Raise Track Update for 2026-10-19. Amount line is $93 million Series A, led by RA Capital Management, with the participants named on this page. Says the total is $103 million. The Investors line does not include the family office.